.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

The New Frontier in NSCLC: Immuno-Oncology Combinations

EP. 1: Implications for Pembrolizumab in NSCLC

June 28th 2018

EP. 2: Pembrolizumab and Chemotherapy in Advanced NSCLC

June 28th 2018

EP. 3: Pembrolizumab: Monotherapy Versus Combination Therapy

June 28th 2018

EP. 4: Metastatic NSCLC: A Look at the IMpower150 Trial

June 28th 2018

EP. 5: Chemotherapy With I-O Therapy in EGFR- or ALK-Mutated NSCLC

June 28th 2018

EP. 6: IPI/NIVO in Metastatic NSCLC

June 28th 2018

EP. 7: Interpreting the Results of CheckMate-227 in NSCLC

June 28th 2018

EP. 8: First-Line Therapy in PD-L1 Advanced NSCLC

June 28th 2018

EP. 9: Baseline Steroid Use in NSCLC

June 28th 2018

EP. 10: Concurrent Chemoradiotherapy in Stage III NSCLC

June 28th 2018

EP. 11: The PACIFIC Trial in Stage 3 NSCLC

June 28th 2018

EP. 12: Implications for Using Durvalumab in Stage 3 NSCLC

June 28th 2018

EP. 13: Neoadjuvant Nivolumab in NSCLC

June 28th 2018

EP. 14: Adjuvant Versus Neoadjuvant Therapy in NSCLC

June 28th 2018

EP. 15: Advanced Squamous NSCLC: The IMpower131 Study

June 28th 2018

EP. 16: Immuno-Oncology in NSCLC: Cost Versus Benefit

June 28th 2018

EP. 17: Emerging Treatment Regimens in Advanced NSCLC

June 28th 2018